Crossmark

Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8

Crossref DOI link: https://doi.org/10.1186/s12885-018-4155-6

Published Online: 2018-02-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sootichote, Rochanawan

Thuwajit, Peti

Singsuksawat, Ekapot

Warnnissorn, Malee

Yenchitsomanus, Pa-thai

Ithimakin, Suthinee

Chantharasamee, Jomjit

Thuwajit, Chanitra
Funding

Funding for this research was provided by:

Faculty of Medicine Siriraj Hospital

Mahidol University
More Information

Article History

Received: 11 July 2017

Accepted: 20 February 2018

First Online: 27 February 2018

Ethics approval and consent to participate

: No human and animal ethics approval was required.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.